Singapore BIOPHARMA PTE. LTD. officially announces the acquisition of exclusive distribution rights for Ferabright® in Singapore.
FEABRIGHT is the first and only FDA-approved iron-based contrast agent for brain MRI in adults with known or suspected intracranial malignant tumors, helping visualize lesions with a disrupted blood-brain barrier.